|1.||Pazdur, Richard: 11 articles (04/2015 - 01/2002)|
|2.||Chan, Andrew T: 11 articles (07/2014 - 01/2004)|
|3.||Fuchs, Charles S: 10 articles (07/2014 - 08/2002)|
|4.||Giovannucci, Edward L: 10 articles (07/2014 - 02/2004)|
|5.||Blight, Andrew R: 8 articles (12/2015 - 10/2009)|
|6.||Henney, Herbert R: 8 articles (09/2015 - 10/2009)|
|7.||Justice, Robert: 8 articles (04/2015 - 10/2008)|
|8.||Cohen, Martin H: 8 articles (01/2012 - 01/2002)|
|9.||Chande, N: 8 articles (01/2008 - 01/2002)|
|10.||Kamin, Marc: 8 articles (12/2005 - 02/2002)|
01/01/2008 - "Tablets 4 and 5, prepared with the highest forces, caused pain during in vivo application and gave rise to irritation needing to be detached by the volunteers while tablet 1, prepared with the lowest force, gave the best results because it was able to produce the highest drug salivary concentration and no pain. "
03/01/2014 - "After an open-label titration period to identify an optimal dose that would provide adequate pain relief for 2 consecutive episodes of BTP with an acceptable level of adverse events, patients were randomly assigned to a double-blind, placebo-controlled, crossover period with 1 of 13 prespecified sequences of 9 tablets (6 tablets of FE of the dose identified during the open-label titration and 3 placebo). "
01/01/1992 - "Spray was significantly superior to tablets in terms of number of patients helped, speed of pain relief and reduction in the number of attacks from pre-study levels. "
12/01/2002 - "There were no significant differences between the groups for either the primary efficacy endpoint, the median time for the injury to be rated as 'completely better' by the patients (>14 days active gel, 13.5 days active tablets; P = 0.59), or for other efficacy measures including the times to clinically significant relief from pain at rest or on movement and swelling. "
11/01/1991 - "At 4 hours there was a significant reduction in pain in subjects who received 120 mg or 90 mg tablets compared with placebo, and in subjects who received 120 mg tablets compared with those who received 60 mg tablets. "
|2.||Migraine Disorders (Migraine)
07/01/2012 - "While current therapies, and, in particular, oral triptan tablets can be effective for many types of migraine attacks that a patient can experience, they may not be the optimum treatment for every migraine in every patient. "
06/01/2006 - "Furthermore, parenteral administration of a triptan is always more likely to provide relief of symptoms than conventional tablets, even when it is used later in the course of the migraine attack. "
01/01/2005 - "Tablets that dissolve rapidly on the tongue without a requirement for extra fluid intake are a popular alternative to conventional tablets, allowing discreet, convenient and early treatment of migraine anywhere and anytime it strikes. "
01/01/2005 - "Patients generally prefer to administer acute migraine therapies orally, but conventional tablets do not suit all patients and situations. "
07/01/2004 - "In addition, the number of abortive anti-migraine tablets was reduced. "
02/01/2009 - "The tightened 95-105% allowable potency range for L-T(4) tablets is a significant improvement, but otherwise acceptable potency differences (whether due to potency decay or lot-by-lot inconsistencies) may be problematic for some patients, for example, those undergoing high-dose L-T(4) therapy for cancer."
08/01/2006 - "Side effects were the main causes of withdrawal (32%), and insufficient therapeutic effect and adverse events for a small number of cases (5.5% and 4.7% respectively), while various causes (fear of cancer, missing tablets, family doctor or other specialist's advice, remission of symptoms) were responsible for terminating treatment after extended periods. "
09/01/2015 - "In this prospective, observational study, cancer patients suffering from sleep problems were treated with B pinnatum (350 mg tablets, corresponding to 50% of leaf pressed juice [Weleda AG, Arlesheim, Switzerland], dosage at physician's consideration, but most frequently 2 tablets with evening meal and 2 before going to bed). "
08/01/2015 - "PK study showed t1/2 of 58 h, Cmax of 17 ng/ml, Tmax of 8 h, AUC0-inf of 1185 ng*hr/ml, Vd/F of 3310 L and CL/F of 41 L/hr. Compared with oral dosing of intact immediate release (IR) tablets, GT administration resulted in 34 % reduction in Cmax and 33-44 % decrease in AUC (all p <0.05) (Jänne et al., Clin Cancer Res 2011). "
09/01/1982 - "This study evaluates the anti-cancer effect of the tablets and its clinical application. "
01/01/2006 - "Prepared buccal tablets were found to be effective for the treatment of viral infections locally within the oral cavity and also for systemic treatment."
08/01/2015 - "The results of this study strongly support the use of delayed-release tablets over suspension in patients at risk for invasive fungal infection. "
01/01/2011 - "In our trial 43 patients with urogenital infections resistant to standard therapy received the same basic therapy (4 tablets of safocid a day for 5 days) which, on demand, was combined with pathogenetic and symptomatic treatment. "
07/01/2007 - "Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study."
09/01/2014 - "Among those receiving PrEP, HIV incidence was 4·7 infections per 100 person-years if drug was not detected in dried blood spots, 2·3 infections per 100 person-years if drug concentrations suggested use of fewer than two tablets per week, 0·6 per 100 person-years for use of two to three tablets per week, and 0·0 per 100 person-years for use of four or more tablets per week (p<0·0001). "
|5.||Asthma (Bronchial Asthma)
09/01/2014 - "In these patients with bronchial asthma, 100 μg/d was the dosage of tratinterol hydrochloride tablets most efficacious in terms of improvement in lung function. "
01/01/1983 - "Intravenous, oral or rectal solutions and plain uncoated tablets are appropriate for acute therapy, while reliably absorbed slow-release formulations offer therapeutic advantages for the management of chronic asthma, particularly in patients with rapid elimination. "
01/01/1990 - "The effectiveness in therapy of childhood asthma could be improved by stronger sustained release effect and different doses of tablets."
07/01/1986 - "Compared with ordinary medication, the slow-release tablets obtained higher morning expiratory peak flow values and an improvement in the asthma symptoms during the night and during exercise (P less than 0.05). "
12/01/2008 - "Tablets were well tolerated and equally effective in monosensitized compared with polysensitized patients and in patients with peak seasonal asthma (patients with perennial asthma were specifically excluded). "
|3.||Morphine (MS Contin)
|7.||Diclofenac (SR 38)
|1.||Drug Therapy (Chemotherapy)